We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for ...

for early Alzheimer’s disease (AD). This decision may simplify the treatment process for patients and care partners. LEQEMBI, designed for patients with mild cognitive impairment (MCI) or mild ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...

A major trial in frontotemporal dementia patients has found that oxytocin can help improve symptoms of apathy. A new study led by Western researchers suggests that frequent treatment with intranasal o ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.

The next Alzheimer’s treatment could come from an unexpected place. In new research released this week, scientists have found ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

Approval was based on results from multiple studies, which demonstrated a slowing of cognitive decline in patients with ...